Komori
Share Issuance and Disposal7776CellSeed Inc.Electrical Equipment and Precision Instruments

Notice Concerning the Monthly Exercise Status of the 25th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)

In April 2026, 1,140 of the 25th Series of Stock Acquisition Rights were exercised, and 114,000 new shares were delivered. As of the end of the month, 42,785 stock acquisition rights remained unexercised.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
114000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status report for stock acquisition rights with an exercise price adjustment clause (25th Series of Stock Acquisition Rights)

発行・処分する株式数

Number of shares delivered during the month: 114,000 shares (114,000 new shares, 0 transferred treasury shares)

発行済株式総数

Exercise ratio subject to exercise restrictions: 0.32% (114,000 shares / 34,666,419 shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices in April 2026: ¥283.24, ¥293.91, ¥279.36, ¥276.45, ¥291.00, ¥282.27, ¥280.33, ¥291.97, ¥292.94, ¥289.06, ¥288.09, ¥270.63 and ¥271.60. Details of the adjustment clause and floor price: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 86,000; unexercised at the end of the month preceding the month covered: 43,925; unexercised at the end of the month covered: 42,785
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
8 December 2025: Issuance of the 25th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause). Amount: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status report for stock acquisition rights with an exercise price adjustment clause (25th Series of Stock Acquisition Rights)
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 114,000 shares (114,000 new shares, 0 transferred treasury shares)
Dilution RateExercise ratio subject to exercise restrictions: 0.32% (114,000 shares / 34,666,419 shares)
Exercise priceExercise prices in April 2026: ¥283.24, ¥293.91, ¥279.36, ¥276.45, ¥291.00, ¥282.27, ¥280.33, ¥291.97, ¥292.94, ¥289.06, ¥288.09, ¥270.63 and ¥271.60. Details of the adjustment clause and floor price: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 86,000; unexercised at the end of the month preceding the month covered: 43,925; unexercised at the end of the month covered: 42,785
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing8 December 2025: Issuance of the 25th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause). Amount: Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 25th Series of Stock Acquisition Rights in April 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of the 25th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) | CellSeed Inc. (7776) timely disclosure | Komori